logo
logo
Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

NASDAQ•EWTX
CEO: Dr. Peter A. Thompson FACP, M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2021-03-26
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
連絡先情報
1715 38th Street, Boulder, CO, 80301, United States
720-262-7002
www.edgewisetx.com
時価総額
$3.18B
PER (TTM)
-20.2
19.5
配当利回り
--
52週高値
$31.29
52週安値
$10.60
52週レンジ
94%
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$0.39+8.33%
直近4四半期の推移

フリーCF

-$34.87M+24.99%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Strong Asset Position Growth Total assets reached $583.5M, driven by $517.3M in marketable securities available for sale as of September 30, 2025.
Research Spending Ramps Up Nine-month R&D expenses rose $17.2M to $107.8M, supporting clinical advancement of lead candidates like sevasemten and EDG-7500.
Capital Inflows Support Operations Financing activities provided $192.1M net cash over nine months, funding operations amid ongoing net losses for drug development.
Common Shares Outstanding Increased Outstanding common shares grew to 105.9M shares following registered direct offerings completed in January 2024 and April 2025.

リスク要因

Increased Operating Cash Usage Net cash used in operating activities increased to $(105.2M) for nine months, necessitating continued reliance on capital raises.
Lead Candidate Development Uncertainty Success hinges on timely clinical completion and regulatory approval for sevasemten and EDG-7500; failure harms the entire business outlook.
Intense Market Competition Noted Significant competition exists from established therapies and other pipeline products in Duchenne and HCM, potentially limiting market acceptance.
Operating Expenses Rising Sharply Total operating expenses increased $22.1M over nine months, driven by R&D advancement costs and increased personnel-related expenses.

見通し

Cash Funds Next Twelve Months Existing cash, cash equivalents, and marketable securities of $563.3M are expected to fund operations for at least the next 12 months.
Advance Key Clinical Stage Programs Expect substantial spending to progress sevasemten, EDG-7500, and EDG-15400 through the remainder of their respective clinical development phases.
Substantial Future Capital Required Substantial additional funding will be required to complete development and commercialization efforts for product candidates if current cash runs low.
G&A Expenses Anticipated Increase General and administrative expenses are expected to increase as headcount grows to support continued research and development programs.

同業比較

売上高 (TTM)

Novavax, Inc.NVAX
$1.06B
+20.3%
Harmony Biosciences Holdings, Inc.HRMY
$825.94M
+21.1%
Galapagos NVGLPG
$316.64M
-3298.7%

粗利益率 (最新四半期)

Galapagos NVGLPG
475.5%
+375.5pp
Viridian Therapeutics, Inc.VRDN
100.0%
+0.0pp
AbCellera Biologics Inc.ABCL
100.0%
+588.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
EWTX$3.18B-20.2-30.9%0.7%
VERA$3.00B-10.9-50.9%14.9%
WVE$2.30B-17.3-75.6%8.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月2日
|
EPS:-$0.43
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.39+8.3%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.34+0.0%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.43+30.3%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.45+7.6%
    不明

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.36-12.2%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.34+0.0%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月9日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.33+6.5%
    不明

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月22日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.57-24.6%
    不明